Work

107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China

Year: 2026

Type: article

Abstract: In HARMONi-2 study, ivonescimab significantly improved progression free survival (PFS) compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer (NSCLC), with manageable safety profile. Here we reported health-related quality of life (HRQoL) from HARMONi-2.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106414

Authors: B. Liu, J. Yao, H. Zhong, J. Li, S. Zhang, Y. Sun, H. Ge, Q. Shi, M. Zhou, Z. Han, J. Wang, Q. Bu, Y. Zhao, G. Li, W. Li, Y.M. Xia, C. Zhou

Institutions: Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Henan University of Science and Technology, Shanghai Chest Hospital, Gannan Medical University, First Affiliated Hospital of Gannan Medical University, Jilin Province Tumor Hospital, Shandong Tumor Hospital, Fourth Hospital of Hebei Medical University, Guangzhou Medical University Cancer Hospital, Chinese PLA General Hospital, Chinese People's Liberation Army, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Henan Cancer Hospital, Kunming Medical University, Shanghai Pulmonary Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

OpenAlex ID: W7138178356

FWCI:

Cites:

Cited by:

Related to: